MicroRNA as an Important Target for Anticancer Drug Development

Abstract

Cancer has become the second greatest cause of death worldwide. Although there are several different classes of anticancer drugs that are available in clinic, some tough issues like side-effects and low efficacy still need to dissolve. Therefore, there remains an urgent need to discover and develop more effective anticancer drugs. MicroRNAs (miRNAs) are a class of small endogenous non-coding RNAs that regulate gene expression by inhibiting mRNA translation or reducing the stability of mRNA. An abnormal miRNA expression profile was found to exist widely in cancer cell, which induces limitless replicative potential and evading apoptosis. MiRNAs function as oncogenes (oncomiRs) or tumor suppressors during tumor development and progression. It was shown that regulation of specific miRNA alterations using miRNA mimics or antagomirs can normalize the gene regulatory network and signaling pathways, and reverse the phenotypes in cancer cells. The miRNA hence provides an attractive target for anticancer drug development. In this review, we will summarize the latest publications on the role of miRNA in anticancer therapeutics and briefly describe the relationship between abnormal miRNAs and tumorigenesis. The potential of miRNA-based therapeutics for anticancer treatment has been critically discussed. And the current strategies in designing miRNA targeting therapeutics are described in detail. Finally, the current challenges and future perspectives of miRNA-based therapy are conferred.

miR-302 Suppresses the Proliferation, Migration, and Invasion of Breast Cancer Cells by Downregulating ATAD2

“…The abnormal expression of miRNAs can result in the development of various pathological events such as cancers. Therefore, miRNAs are considered therapeutic, diagnostic, and prognostic factors in various human cancers [ 29 ]. Recent studies have demonstrated that several miRNAs suppress cancer cell proliferation and progression.…”

From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer

“…Other methods of miR-21 inhibition can target specific steps in miRNA biogenesis. For example, the small-molecule inhibitors diazobenzene and estradiol, have been used to target specific steps in miRNA biogenesis such as transcription [ 154 , 155 , 156 ]. In other efforts, the miRNA structure has been directly targeted by using small molecules to bind to the G-hairpin of the hTERT-G-quadruplex-forming sequence and thereby downregulate expression.…”

Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential

“…to screen ncRNAs ( 216 ). Second, multi-targeting of endogenous RNAs may be risky for a therapeutic process, and the resulting off-target effects need to be addressed ( 231 ). Third, appropriate in vivo and in vitro models need to be established to confirm the structure-function relationships, potency, and specificity.…”